Logo image of CML.MI

COMAL SPA (CML.MI) Stock Fundamental Analysis

BIT:CML - Euronext Milan - IT0005428971 - Common Stock - Currency: EUR

5.08  +0.26 (+5.39%)

Fundamental Rating

4

CML gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. CML has a bad profitability rating. Also its financial health evaluation is rather negative. CML shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CML had positive earnings in the past year.
CML had a negative operating cash flow in the past year.
In the past 5 years CML has always been profitable.
CML had negative operating cash flow in 4 of the past 5 years.
CML.MI Yearly Net Income VS EBIT VS OCF VS FCFCML.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 5M -5M -10M

1.2 Ratios

The last Return On Invested Capital (14.56%) for CML is above the 3 year average (10.49%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.83%
ROE 20.81%
ROIC 14.56%
ROA(3y)2.62%
ROA(5y)2.89%
ROE(3y)17.19%
ROE(5y)19.48%
ROIC(3y)10.49%
ROIC(5y)12.54%
CML.MI Yearly ROA, ROE, ROICCML.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 10 20 30

1.3 Margins

CML's Profit Margin has improved in the last couple of years.
CML's Operating Margin has improved in the last couple of years.
In the last couple of years the Gross Margin of CML has grown nicely.
Industry RankSector Rank
OM 14.12%
PM (TTM) 6.97%
GM 44.47%
OM growth 3Y5.5%
OM growth 5Y21.45%
PM growth 3Y7.89%
PM growth 5Y26.25%
GM growth 3Y9.58%
GM growth 5Y17.09%
CML.MI Yearly Profit, Operating, Gross MarginsCML.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 10 20 30 40

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CML is creating value.
Compared to 1 year ago, CML has about the same amount of shares outstanding.
CML has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CML has been reduced compared to a year ago.
CML.MI Yearly Shares OutstandingCML.MI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
CML.MI Yearly Total Debt VS Total AssetsCML.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

CML has an Altman-Z score of 0.74. This is a bad value and indicates that CML is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.67 indicates that CML is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Altman-Z 0.74
ROIC/WACC2.1
WACC6.95%
CML.MI Yearly LT Debt VS Equity VS FCFCML.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

A Current Ratio of 1.11 indicates that CML should not have too much problems paying its short term obligations.
A Quick Ratio of 0.36 indicates that CML may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.11
Quick Ratio 0.36
CML.MI Yearly Current Assets VS Current LiabilitesCML.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

9

3. Growth

3.1 Past

CML shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.55%, which is quite impressive.
CML shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 55.95% yearly.
The Revenue has decreased by -3.02% in the past year.
Measured over the past years, CML shows a very strong growth in Revenue. The Revenue has been growing by 23.83% on average per year.
EPS 1Y (TTM)22.55%
EPS 3Y51.98%
EPS 5Y55.95%
EPS Q2Q%-0.7%
Revenue 1Y (TTM)-3.02%
Revenue growth 3Y41.46%
Revenue growth 5Y23.83%
Sales Q2Q%-13.6%

3.2 Future

The Earnings Per Share is expected to grow by 21.72% on average over the next years. This is a very strong growth
Based on estimates for the next years, CML will show a very strong growth in Revenue. The Revenue will grow by 36.31% on average per year.
EPS Next Y13.97%
EPS Next 2Y21.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year99.15%
Revenue Next 2Y51.57%
Revenue Next 3Y54.8%
Revenue Next 5Y36.31%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CML.MI Yearly Revenue VS EstimatesCML.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
CML.MI Yearly EPS VS EstimatesCML.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.1 0.2 0.3 0.4 0.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 14.51 indicates a correct valuation of CML.
CML is valuated cheaply when we compare the Price/Earnings ratio to 29.35, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 12.57, CML is valued correctly.
CML is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 14.51
Fwd PE 12.57
CML.MI Price Earnings VS Forward Price EarningsCML.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.82
CML.MI Per share dataCML.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

CML's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as CML's earnings are expected to grow with 21.72% in the coming years.
PEG (NY)1.04
PEG (5Y)0.26
EPS Next 2Y21.72%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CML!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMAL SPA

BIT:CML (3/7/2025, 7:00:00 PM)

5.08

+0.26 (+5.39%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners5.11%
Inst Owner ChangeN/A
Ins Owners15.28%
Ins Owner ChangeN/A
Market Cap66.50M
Analysts80
Price Target5.81 (14.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 14.51
Fwd PE 12.57
P/S 1.12
P/FCF N/A
P/OCF N/A
P/B 3.35
P/tB 3.98
EV/EBITDA 8.82
EPS(TTM)0.35
EY6.89%
EPS(NY)0.4
Fwd EY7.95%
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS4.53
BVpS1.52
TBVpS1.28
PEG (NY)1.04
PEG (5Y)0.26
Profitability
Industry RankSector Rank
ROA 1.83%
ROE 20.81%
ROCE 23.62%
ROIC 14.56%
ROICexc 27.65%
ROICexgc 32.88%
OM 14.12%
PM (TTM) 6.97%
GM 44.47%
FCFM N/A
ROA(3y)2.62%
ROA(5y)2.89%
ROE(3y)17.19%
ROE(5y)19.48%
ROIC(3y)10.49%
ROIC(5y)12.54%
ROICexc(3y)16.97%
ROICexc(5y)17.84%
ROICexgc(3y)19.48%
ROICexgc(5y)20.06%
ROCE(3y)16.74%
ROCE(5y)19.7%
ROICexcg growth 3Y20.75%
ROICexcg growth 5Y17.56%
ROICexc growth 3Y20.8%
ROICexc growth 5Y14.05%
OM growth 3Y5.5%
OM growth 5Y21.45%
PM growth 3Y7.89%
PM growth 5Y26.25%
GM growth 3Y9.58%
GM growth 5Y17.09%
F-Score3
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Debt/EBITDA 1.34
Cap/Depr 265.46%
Cap/Sales 7.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.11
Quick Ratio 0.36
Altman-Z 0.74
F-Score3
WACC6.95%
ROIC/WACC2.1
Cap/Depr(3y)308.58%
Cap/Depr(5y)270.83%
Cap/Sales(3y)7.68%
Cap/Sales(5y)6.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.55%
EPS 3Y51.98%
EPS 5Y55.95%
EPS Q2Q%-0.7%
EPS Next Y13.97%
EPS Next 2Y21.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-3.02%
Revenue growth 3Y41.46%
Revenue growth 5Y23.83%
Sales Q2Q%-13.6%
Revenue Next Year99.15%
Revenue Next 2Y51.57%
Revenue Next 3Y54.8%
Revenue Next 5Y36.31%
EBIT growth 1Y45.55%
EBIT growth 3Y49.24%
EBIT growth 5Y50.39%
EBIT Next Year81.84%
EBIT Next 3Y44.34%
EBIT Next 5Y32.69%
FCF growth 1Y23.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.82%
OCF growth 3YN/A
OCF growth 5YN/A